Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
about
Molecular substratification of bladder cancer: moving towards individualized patient managementCurrent concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ systemUnderstanding the molecular pathogenesis and prognostics of bladder cancer: an overviewEmerging critical role of molecular testing in diagnostic genitourinary pathologyDifferential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylationSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis.A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.ROMA: Representation and Quantification of Module Activity from Target Expression Data.Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancerCopy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterationsLogic Learning Machine creates explicit and stable rules stratifying neuroblastoma patientsExpression of histone deacetylases 1, 2 and 3 in urothelial bladder cancerIntegrative epigenomic analysis of differential DNA methylation in urothelial carcinoma.Modelling bladder cancer in mice: opportunities and challenges.A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancersThe UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens.An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancerIdentification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaThree differentiation states risk-stratify bladder cancer into distinct subtypesInvestigating inter-chromosomal regulatory relationships through a comprehensive meta-analysis of matched copy number and transcriptomics data setsSignificant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma.PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest.DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation statusCyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis.The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer.Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder CancerCombination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
P2860
Q26744343-031429A4-2CEB-4399-B59B-7BD743B7397AQ26748510-3D6E97E6-5854-41BB-8E74-75BD90624D75Q26752921-60F1932E-8072-45C4-8389-950B86048152Q27021371-AA84FCDE-7F22-4978-AA5C-6507EAB2BCA0Q28730029-E0B69DA0-C0E6-47A8-851B-A75785F4272EQ30240816-C86DE553-AE82-45E5-BF7B-21023A9E4015Q30279180-7CF75E9C-B339-4A76-AB61-F7B2F711D45EQ30416201-F62E5434-7663-407E-8B05-A16F7C7202E6Q30421675-D63DE52C-DE90-47D6-BE39-7AF179C70AF9Q30838620-F18B2A20-5351-4024-A756-8268CFBF344AQ30844284-088E9932-31CF-4733-8209-6E0B72092BA4Q30857433-0285AC5C-7C3C-4EFD-ADEB-0F43DD1B4562Q31049998-E5FAD02E-4FAF-4BCC-8C57-581E370D4CE7Q33593041-C3BEB247-F230-4819-80FD-881D95430249Q33886553-C4783CC2-82F5-40B6-B416-F4FA6483FD41Q34299788-839F3DA1-7F07-4802-948B-5AD29D9C72D1Q34563208-308E3797-5966-44EA-8DAC-0F57FECA2BA9Q34734078-2B1E24E1-8D54-4184-BBF2-D5CA5AA17A51Q34787791-AB65595B-6770-461B-9A78-36393D2163E0Q35119480-DD15F3CB-B47A-454B-920D-4593EBDE4237Q35215704-E65BD02D-DAAF-4602-98E7-798073A3B8BBQ35285703-95B72341-8F65-43D7-8639-1FFA81699392Q35624169-77809C55-2E37-4FF8-822C-4FFCC03A6166Q35638497-381A0C61-2D82-46A1-B109-31C1848C275EQ35655215-F326D433-2371-4EEA-8AA5-70971A41C1E5Q35678922-A5B4485D-D801-4330-9C6F-AFBAB79E1530Q35731224-B4130898-5BD1-44DD-9560-8F36C963A5B6Q35750975-6D4A7999-E25D-4F59-A5F0-ACC845539C1BQ35845694-C068B5B3-EA22-4079-BBB7-11E696CD915BQ35865635-BE842682-02FF-4C45-9E50-29E585522BEBQ36140798-5C2CFF1A-6C15-42D5-AA7B-10F1EC8CB174Q36187834-6CD9F2A4-A3F1-43F6-9DDB-363825E85A59Q36232504-6A7F5386-0924-4787-BA66-F84FB20C75B2Q36328938-6F892ABB-C4BB-4328-B721-9E3B4FCB4ED4Q36393217-7DE65EF3-2256-4DBE-A647-F07ADEF723FBQ36526008-252B6252-FF0A-4F70-A52B-318CBFC0DC93Q36600567-417EA677-7001-4174-BF40-58A68B5A0453Q37012561-4921EDB3-2B29-44CC-91E7-F8B6040DEC6DQ37053995-E52AC4FF-93D6-4FF4-860A-6634C5BC33C7Q37341453-2EED054D-9E90-451A-BE22-6511B8BB11BB
P2860
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Combined gene expression and g ...... molecular grading and outcome.
@en
Combined gene expression and g ...... molecular grading and outcome.
@nl
type
label
Combined gene expression and g ...... molecular grading and outcome.
@en
Combined gene expression and g ...... molecular grading and outcome.
@nl
prefLabel
Combined gene expression and g ...... molecular grading and outcome.
@en
Combined gene expression and g ...... molecular grading and outcome.
@nl
P2093
P1433
P1476
Combined gene expression and g ...... molecular grading and outcome.
@en
P2093
Attila Frigyesi
Christer Hallden
David Lindgren
Fredrik Liedberg
Gottfrid Sjödahl
Gunilla Chebil
Sigurdur Gudjonsson
Tobias Ryden
Wiking Månsson
P304
P356
10.1158/0008-5472.CAN-09-4213
P407
P577
2010-04-20T00:00:00Z